Home › Diabetes › Tennessee › Memphis
Diabetes clinical trials in Memphis, TN
4 studies for Diabetes are looking for participants at sites in and around Memphis (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)
RecruitingPhase 1/2
- Le Bonhuer Children's, Memphis
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
RecruitingPhase 2/3
- Lt. Col. Luke Weathers, Jr. VA Medical Center, Memphis
Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer
RecruitingObservational study
- Methodist LeBonheur Healthcare, Memphis
Pharmacy-led Transitions of Care Intervention to Improve Medication Adherence
Recruiting
- University of Tennessee Health Science Center/Regional One Health, Memphis
About Diabetes
Diabetes is a chronic health condition in which your blood glucose levels are too high. There is no cure, but diet, exercise, medications, and weight control can help.
More about Diabetes on MedlinePlus
Diabetes trials in other cities
- Boston, MA22 studies
- New York City, NY16 studies
- Chicago, IL16 studies
- Houston, TX15 studies
- Aurora, CO13 studies
- Durham, NC13 studies
- Baltimore, MD12 studies
- Philadelphia, PA11 studies
- Los Angeles, CA10 studies
- San Diego, CA10 studies
- Indianapolis, IN10 studies
- Pittsburgh, PA9 studies
Other studies in Memphis
- Cancer (all types)30 studies
- Non-Small Cell Lung Cancer25 studies
- Breast Cancer21 studies
- Sickle Cell Disease19 studies
- Acute Lymphoblastic Leukemia17 studies
- Lung Cancer17 studies
- Acute Myeloid Leukemia14 studies
- Heart Failure12 studies
- Melanoma11 studies
- Soft Tissue Sarcoma10 studies
- Colorectal Cancer10 studies
- Type 2 Diabetes10 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.